|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: OPCML |
Gene summary for OPCML |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | OPCML | Gene ID | 4978 |
| Gene name | opioid binding protein/cell adhesion molecule like | |
| Gene Alias | IGLON1 | |
| Cytomap | 11q25 | |
| Gene Type | protein-coding | GO ID | GO:0007155 | UniProtAcc | Q14982 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 4978 | OPCML | HTA11_866_2000001011 | Human | Colorectum | AD | 1.82e-03 | 1.06e-01 | -0.1001 |
| 4978 | OPCML | HTA11_1391_2000001011 | Human | Colorectum | AD | 9.68e-03 | 1.73e-01 | -0.059 |
| 4978 | OPCML | HTA11_6818_2000001011 | Human | Colorectum | AD | 2.97e-27 | 1.13e+00 | 0.0112 |
| 4978 | OPCML | HTA11_6818_2000001021 | Human | Colorectum | AD | 1.43e-15 | 4.91e-01 | 0.0588 |
| 4978 | OPCML | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 1.99e-02 | 4.77e-01 | 0.3487 |
| 4978 | OPCML | HTA11_99999971662_82457 | Human | Colorectum | MSS | 2.03e-09 | 2.48e-01 | 0.3859 |
| 4978 | OPCML | HTA11_99999974143_84620 | Human | Colorectum | MSS | 1.29e-06 | 2.01e-01 | 0.3005 |
| 4978 | OPCML | Pat04-B | Human | Stomach | GC | 8.51e-05 | 1.92e-01 | -0.1483 |
| 4978 | OPCML | Pat06-B | Human | Stomach | GC | 8.54e-10 | 2.34e-01 | -0.1961 |
| 4978 | OPCML | Pat11-B | Human | Stomach | GC | 7.11e-10 | 2.92e-01 | -0.182 |
| 4978 | OPCML | Pat15-B | Human | Stomach | GC | 2.00e-25 | 5.38e-01 | -0.0778 |
| 4978 | OPCML | Pat18-B | Human | Stomach | GC | 7.15e-04 | 1.61e-01 | -0.0432 |
| 4978 | OPCML | Pat24-B | Human | Stomach | GC | 8.07e-05 | 2.14e-01 | -0.1184 |
| 4978 | OPCML | Pat26-A | Human | Stomach | CSG | 1.95e-05 | 1.76e-01 | -0.2402 |
| 4978 | OPCML | Pat28-A | Human | Stomach | CSG | 4.94e-15 | 3.29e-01 | -0.2594 |
| 4978 | OPCML | Pat29-A | Human | Stomach | CAG with IM | 1.57e-13 | 4.61e-01 | -0.2769 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| OPCML | deletion | Frame_Shift_Del | c.645delA | p.Val216Ter | p.V216* | Q14982 | protein_coding | TCGA-D8-A1JK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |||
| OPCML | deletion | Frame_Shift_Del | novel | c.821delN | p.Asn274ThrfsTer8 | p.N274Tfs*8 | Q14982 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| OPCML | SNV | Missense_Mutation | rs772092757 | c.229G>A | p.Ala77Thr | p.A77T | Q14982 | protein_coding | tolerated(0.13) | possibly_damaging(0.678) | TCGA-C5-A8XI-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | SD |
| OPCML | SNV | Missense_Mutation | novel | c.200C>T | p.Ala67Val | p.A67V | Q14982 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| OPCML | SNV | Missense_Mutation | c.157N>A | p.Ala53Thr | p.A53T | Q14982 | protein_coding | deleterious(0.03) | possibly_damaging(0.473) | TCGA-LP-A4AW-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| OPCML | SNV | Missense_Mutation | rs372426856 | c.625N>A | p.Ala209Thr | p.A209T | Q14982 | protein_coding | deleterious(0.02) | possibly_damaging(0.802) | TCGA-ZJ-AAXT-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
| OPCML | SNV | Missense_Mutation | c.432N>A | p.Asp144Glu | p.D144E | Q14982 | protein_coding | deleterious(0) | benign(0.257) | TCGA-AA-3844-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | capecitabine | PD | |
| OPCML | SNV | Missense_Mutation | rs770223558 | c.211C>T | p.Arg71Cys | p.R71C | Q14982 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-3949-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| OPCML | SNV | Missense_Mutation | c.328G>A | p.Glu110Lys | p.E110K | Q14982 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| OPCML | SNV | Missense_Mutation | c.991N>A | p.Leu331Ile | p.L331I | Q14982 | protein_coding | tolerated(0.26) | benign(0.019) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 4978 | OPCML | DRUGGABLE GENOME | methylphenidate | METHYLPHENIDATE | 29382897 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |